You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 266 Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient’s plasma – a prospective trial

Article Text

Article menu

Download PDFPDF

Ovarian cancer
266 Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient’s plasma – a prospective trial
Free
  1. D Eichkorn1,
  2. A Hasenburg2,
  3. F Vosshagen3,
  4. E Obermayr4,
  5. A Geroldinger5,
  6. R Zeillinger6 and
  7. M Bossart7
  1. 1Schwarzwald-Baar Clinics, Department of Obstetrics and Gynecology , Villingen-Schwenningen, Germany
  2. 2University Medical Center Mainz, Department of Obstetrics and Gynecology, Mainz, Germany
  3. 3Ortenau Clinics , Department of Anesthesiology, Lahr/Schwarzwald, Germany
  4. 4Medical University of Vienna, Department of Obstetrics and Gynecology, Wien, Austria
  5. 5Medical University of Vienna, Section for Clinical Biometrics, Center for Medical Statistics, Wien, Austria
  6. 6Medical University of Vienna, Department of Obstetrics and Gynecology, Vienna, Austria
  7. 7St. Josefskrankenhaus, Freiburg, Obstetrics, Gynecology and Gynecologic Oncology, Freiburg im Breisgau, Germany

Abstract

Introduction/Background*Trial on five plasma biomarkers (CA125 – cancer antigen 125, HE4 – human epididymis protein 4, OPN - osteopontin, leptin, prolactin) and their possible role in differentiating benign from malignant ovarian tumors.

Methodology In this unicentric prospective trial preoperative blood samples of 43 women with ovarian masses determined for ovarian surgery were analyzed. 25 patients had pathologically confirmed benign, 18 malignant ovarian tumors. Blood plasma was analyzed for CA125, HE4, OPN, leptin, prolactin and MIF (macrophage migration inhibitory factor) by multiplex immunoassay analysis. Each single protein and a logistic regression model including all the listed proteins were tested as preoperative predictive marker for suspect ovarian masses.

Result(s)*Plasma CA125 was confirmed as a highly accurate tumor marker in ovarian cancer. HE4, OPN, leptin and prolactin plasma levels differed significantly between benign and malignant ovarian masses. With a logistic regression model a formula including CA125, HE4, OPN, leptin and prolactin was developed to predict malignant ovarian tumors. With a discriminatory AUC (area under the curve) of 0.96 it showed to be a highly sensitive and specific diagnostic test for a malignant ovarian tumor.

Abstract 266 Figure 1
Abstract 266 Figure 1

Patient recruitment. Patients were recruited from the Department of Gynecology at Freiburg University Hospital between July 2013 and July 2015. Data and samples of 43 of the patients were analyzed with an age range of 19 to 81 years

Conclusion*The calculated formula with the combination of CA125, HE4, OPN, leptin and prolactin plasma levels surpasses each single marker in its diagnostic value to discriminate between benign and malignant ovarian tumors. The formula, applied to our patient population was highly accurate but should be validated in a larger cohort.

https://doi.org/10.1136/ijgc-2021-ESGO.371

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.